logo-loader

Faron Pharma confident Traumakine could be ‘very effective’ for ARDS subgroup

Published: 08:37 05 Dec 2018 EST

Faron Pharma (LON:FARN) CEO Markku Jalkanen tells Proactive London’s Andrew Scott he's confident their Traumakine drug has the potential to treat around a third of acute respiratory distress syndrome (ARDS) patients in Europe and North America

ARDS is a life-threatening ailment caused by an inflammation of the lungs that usually coincides with illnesses such as pneumonia or severe flu.

Following on from a phase III trial of Traumakine earlier this year scientists have discovered that patients with a particular type of genetic mutation - called a C/T mutation - were almost six times more likely to survive than those who were also taking the drug but didn’t have the mutation

Faron will now liaise with European and US regulators to figure out the next best step for the drug.

Faron Pharmaceuticals outlines groundbreaking work in cancer treatment -...

Dr. Markku Jalkanen, CEO of Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF), delivered a pivotal presentation on the company's groundbreaking work in cancer treatment, focusing on the reprogramming of myeloid cells to combat cancer at the Proactive One2One Investor Conference. Myeloid...

on 02/01/2024